

LIVING WITH LUPUS IN 2020

COUNTRY LEVEL DATA

Portugal



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY:	Portugal				
		DEM	OGRAPHICS:		
	<u>Portugal</u>	<u>EUROPE</u>	Age_	<u>Portugal</u>	<u>EUROPE</u>
Total number of responses	195	4375	Up to 25	4.1%	6.4%
			26 to 35	16.4%	17.9%
<u>Gender</u>	<u>Portugal</u>	<u>EUROPE</u>	36 to 45	39.0%	27.4%
Man	3.6%	3.7%	46 to 55	27.7%	26.6%
Woman	96.4%	95.6%	56 to 65	9.7%	14.8%
Other / prefer not to answer	0.0%	0.7%	above 65	2.6%	5.1%
Total	100.0%	100.0%	NA	0.5%	1.8%
			Grand Total	100.0%	100.0%
		D	IAGNOSIS		
<u>Diagnosis</u>	<u>Portugal</u>	EUROPE	Time to Diagnosis	<u>Portugal</u>	<u>EUROPE</u>
SLE	95.4%	94.4%	Within the year	27.8%	26.5%
Child onset SLE	4.6%	5.6%	1 year	29.4%	21.1%
Grand Total	100.0%	100.0%	2 years	9.6%	11.5%
			3 years	7.0%	5.7%
Prior Diagnosis received before "Lupus"	<u>Portugal</u>	<u>EUROPE</u>	4 years	1.6%	4.6%
None	57.4%	53.7%	5 years	4.8%	4.4%
UCTD/MCTD	1.0%	6.7%	6 years	3.7%	2.9%
Sjogren	1.5%	4.7%	7 years	3.2%	2.7%
APS	1.5%	2.4%	8 years	1.1%	2.4%
Other Autoimmune or Rheumatic	17.9%	13.8%	9 years	2.7%	2.3%
Fibromyalgia	4.6%	5.8%	10 to 20 years	7.0%	10.4%
Psychologic or mental disorder	6.7%	8.9%	More than 20 years	2.1%	5.5%
Other prior diagnosis	12.8%	16.5%	Grand Total	100.0%	100.0%
n=	189	4,275	n=	187	4,154



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

185

n=

4024

		11.45.455.65.65	2000		
		IMPACT ON STU	DIES & CAREER		
Education level	<u>Portugal</u>	<u>EUROPE</u>	Employment level	<u>Portugal</u>	EUROPE
Basic	2.7%	3.7%	Employed full time	56.6%	34.6%
Secundary	43.1%	53.9%	Employed part time	3.7%	16.5%
Academic	54.3%	42.5%	Self-employed full time	6.9%	3.0%
n=	188	4,150	Self-employed part time	1.6%	2.4%
			Looking for employment	7.9%	5.1%
Economic profile	<u>Portugal</u>	<u>EUROPE</u>	Stopped work for medical reason	8.5%	14.7%
No difficulties paying all bills	41.0%	46.9%	Retired	6.9%	11.6%
Occasional difficulties paying all bills.	34.4%	26.8%	Student	2.1%	4.0%
Often difficulties paying all bills	8.7%	10.4%	No paid employment / Full time home	1.6%	4.7%
Always difficulty paying all bills	9.7%	7.1%	Other / prefer not to answer	4.2%	3.5%
Did not respond	6.2%	8.9%			
n=	195	4375	n=	189	4247
IMPACT ON STUDIES	<u>Portugal</u>	<u>EUROPE</u>	IMPACT ON CAREER	<u>Portugal</u>	EUROPE
Chose more relevant studies	1.6%	3.1%	No impact	41.6%	32.5%
could not do what they wanted	8.5%	11.1%	Changed career/ job	11.9%	13.5%
needed special support and received it	2.1%	4.6%	moved to Flexible hours	9.2%	8.1%
needed support but did NOT receive it	2.6%	2.9%	Reduced Work Schedule	4.9%	18.5%
Overall negative effect	13.2%	13.5%	Stopped work, gets social allowances	10.3%	18.5%
Overall positive effect	1.1%	1.4%	Missed promotion opportunities	11.9%	9.5%
No impact	73.5%	69.8%	Employment was terminated	5.4%	8.4%
			Other negative impact	28.1%	20.8%
n=	189	4240	Other positive impact	0.5%	1.8%
			Overall had negative impact	47.0%	57.9%



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

		IMPACT ON SC	OCIAL / FAMILY		
Civil status	Portugal	EUROPE	Have children	Portugal	EUROPE
Child/young with family	1.6%	4.5%	None	36.0%	32.8%
Single	19.5%	17.4%	One child	31.2%	23.8%
Married / with partner	66.5%	66.9%	2 or more children	31.2%	38.9%
Divorced	9.2%	9.2%	Child/young living with family	1.6%	4.5%
Widowed	3.2%	2.0%			
n=	185	4206	n=	189	4288
Would have liked more children	<u>Portugal</u>	<u>EUROPE</u>	Faced Misscariages	<u>Portugal</u>	EUROPE
A. Yes	38.5%	37.6%	A. One miscarriage	15.8%	18.4%
B. No	42.0%	37.7%	B. Some miscarriages	9.0%	8.5%
C. don't know / prefer not to answer	19.5%	24.7%	C. Many miscarriages	1.7%	2.9%
			D. No miscarriage	73.4%	70.2%
n (women only) =	174	3,645	n (women only) =	177	3,756
Difficulty to cope with Daily activities	<u>Portugal</u>	<u>EUROPE</u>	More or less active than others same age	<u>Portugal</u>	EUROPE
No Problem at all 1	20.9%	16.2%	Less active due to lupus	67.6%	72.6%
2	36.9%	32.3%	Equally active	23.9%	15.6%
3	33.2%	34.3%	More active due to lupus	2.1%	3.6%
4	9.1%	15.4%	I don't know	6.4%	8.1%
Fully Unable 5	0.0%	1.8%			
n=	187	4226	n=	188	4212
Impact on Sexual/emotional life	<u>Portugal</u>	<u>EUROPE</u>	Negative Impact on couple	<u>Portugal</u>	<u>EUROPE</u>
Negative impact	33.9%	38.2%	It created tensions	35.7%	33.2%
Mixed Positive and negative	38.7%	36.2%	It is difficult for me	66.7%	68.4%
No significant impact	25.8%	23.9%	It is difficult for my partner	9.5%	26.7%
Positive impact	1.6%	1.6%	I am concerned for my couple	10.3%	13.2%
			Our relationship ended	15.1%	16.6%
n=	186	4,204	n=	126	2875



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

n=

187

4197

			DI	SEASE ACTIVITY		
Lupus was under control past 3 mont	:hs	<u>Portugal</u>	<u>EUROPE</u>	Number of symptoms (list of 23)	<u>Portugal</u>	<u>EUROPE</u>
Yes		73%	72%	1	3.2%	1.6%
No		27%	28%	2	2.7%	2.1%
				3	5.9%	4.4%
	n=	192	4347	4	6.4%	5.9%
				5	4.8%	6.1%
				6	10.7%	8.5%
		<u>Portugal</u>	EUROPE	7	11.2%	9.3%
Average nr of symptoms (list of 23)		8.2	8.8	8	8.6%	10.4%
	n=	187	4197	9	10.7%	10.1%
				10	7.5%	9.3%
				11	8.6%	8.3%
		<u>Portugal</u>	EUROPE	12	5.3%	7.0%
Median number of symptoms		8	9	13	8.6%	5.8%
	n=	187	4197	14	2.1%	4.4%
				15	1.6%	2.7%
				16	0.5%	2.1%
				17	1.6%	1.1%
				18	0.0%	0.4%
				19	0.0%	0.3%
				20	0.0%	0.0%



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Symptoms or Features experienced / Most bothersome

	Portu	σal		EURO)PF
	Regularly	Top 3 most	l	Regularly	Top 3 most
Patient reported Symptoms or features	experience	bothersome	Patient reported Symptoms or features	experience	bothersome
A. Rash	34%	11%	A. Rash	40%	9%
B. Sun sensitivity	66%	22%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	35%	6%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	45%	3%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	46%	1%	E. Dryness of the skin	57%	4%
F. Hair loss	60%	18%	F. Hair loss	53%	14%
G. Pain / swelling in joints	81%	50%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	28%	9%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	62%	34%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	45%	17%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	78%	45%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	18%	1%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	15%	2%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	50%	20%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	23%	5%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	43%	9%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	20%	12%	Q. Kidney problems	20%	11%
R. Chest pain	16%	2%	R. Chest pain	24%	4%
S. High Blood pressure	20%	3%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	14%	6%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	19%	8%	U. Osteoporosis	19%	5%
n=	195	178	n=	4375	4084



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			MEDICA	ATION		
		<u>Portugal</u>	<u>EUROPE</u>		<u>Portugal</u>	<u>EUROPE</u>
Average number of medication (from	<u>list</u>			Median number of medication (from		
<u>of 16)</u>		5.5	5.2	<u>list of 16)</u>	5	5
	n=	179	4099	n=	179	4099
Number of medications (list of 16)		<u>Portugal</u>	<u>EUROPE</u>	% using given medication type:	<u>Portugal</u>	EUROPE
	1	5.6%	5.4%	Non Steroids Anti-Inflammatory	44.1%	32.9%
	2	6.7%	9.0%	Antimalarials	74.3%	75.0%
	3	10.6%	12.5%	Oral Steroids	69.8%	52.4%
	4	14.5%	14.1%	Immunosuppressants	41.9%	39.8%
	5	14.0%	14.8%	Biologics	9.5%	10.9%
	6	14.0%	13.9%	Painkillers	46.9%	50.1%
	7	11.7%	11.8%	Antidepressant	30.2%	17.0%
	8	11.7%	9.0%	Anxiolytic	27.9%	11.7%
	9	6.7%	5.1%	Anticoagulants	21.8%	16.6%
	10	1.7%	2.5%	Thyroid medication	7.8%	14.8%
	11	2.2%	1.1%	Blood circulation and heart	18.4%	23.3%
	12	0.0%	0.4%	Stomach protection	50.8%	47.0%
	13	0.6%	0.2%	Statins	4.5%	5.9%
				Calcium	30.2%	29.7%
	n=	179	4099	Vitamin D	59.2%	68.4%
				Vitamins (excl.D) / mineral complements	10.1%	25.4%



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to	<u>Portugal</u>	<u>EUROPE</u>	HrQoL dimensions	<u>Portugal</u>	<u>EUROPE</u>
Average scores (1 Fully disage	ree - 5 fully agree)		AVERAGE SCORES (1=FULLY ABLE,	, 5= FULLY UNA	ABLE)
Experienced lupus doctors	3.97	3.81	Mobility	2.25	2.22
Multidisciplinary team	3.38	3.28	Self care	1.74	1.71
Specialised nurses that know lupus	2.84	2.92	Daily Activities	2.30	2.54
Prescribed medication	4.41	4.08	Pain or discomfort	3.23	3.14
Affordable treatments	3.75	3.77	Anxiety or depression	3.20	2.96
Social support and benefits	2.78	2.78	Average	2.54	2.51
Physiotherapy, Rehab, Occupational Thera	a 2.55	2.77			
Professional psychological support	2.67	2.68			
n min	119	3126	n min	186	4196
n max	172	3842	n max	188	4240
Worry about lupus progressing?	<u>Portugal</u>	<u>EUROPE</u>			
Very Low (1-2)	1.1%	3.6%			
Low (3-4)	5.0%	9.3%			
Mid (5-6)	21.8%	24.5%			
High (7-8)	44.7%	41.0%			
Very high (9-10)	27.4%	21.6%			
n=	179	4042			



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Impact of lupus not being under control over past 3 months

	% (of Health Related	l OoL Maintaine	ed vs 100% = FULL HEALTH/ABILITY TO PERFORM		_
	<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	Portug		······································	EURO	PE
		lupus under	not under		lupus under	not under
		<u>control</u>	<u>control</u>		<u>control</u>	<u>control</u>
Mobility		72%	60%	Mobility	73%	59%
Self care		85%	72%	Self care	86%	73%
Daily Activities		70%	59%	Daily Activities	66%	51%
Pain or discomfort		48%	35%	Pain or discomfort	51%	35%
Anxiety or depression		48%	38%	Anxiety or depression	54%	44%
Average		65%	53%	Average	66%	52%
n	n min	137	49	n min	3011	1179
n	max	138	50	n max	3042	1194
		Portug	gal		EURO	PE
		lupus under	not under	More or less active than others of same	lupus under	not under
More or less active than others of same a	ge	control	control	age	control	control
Less active due to lupus		63.8%	78.0%	Less active due to lupus	68.6%	83.0%
Equally active		28.3%	12.0%	Equally active	18.8%	7.6%
More active due to lupus		2.9%	0.0%	More active due to lupus	4.0%	2.7%
I don't know		5.1%	10.0%	I don't know	8.7%	6.7%
	n=	138	50	n=	3018	1189
		Portug	gal		EURO	PE
		lupus under	not under		lupus under	not under
Impact on Sexual/emotional life		control	control	Impact on Sexual/emotional life	control	control
Negative impact		31.4%	40.8%	Negative impact	34.0%	49.0%
Mixed + and -		36.5%	44.9%	Mixed + and -	36.4%	35.7%
No significant impact		30.7%	12.2%	No significant impact	27.8%	14.1%
Positive impact		1.5%	2.0%	Positive impact	1.8%	1.2%
	n=	137	49	n=	3018	1181



DATA FOR: Portugal

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT OF A PROMPT DIAGNOSIS

% of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	<u>Portu</u>	<u>ıgal</u>		EURC	<u>)PE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	70%	63%	Mobility	75%	62%
Self care	83%	76%	Self care	86%	76%
Daily Activities	71%	58%	Daily Activities	67%	53%
Pain or discomfort	48%	36%	Pain or discomfort	52%	39%
Anxiety or depression	43%	42%	Anxiety or depression	52%	49%
Average	63%	55%	Average	66%	56%
Difference		-8%	Difference		-10%
of which - explained by age (*)		-3%	of which - explained by age		-3%
n min	105	45	n min	1926	1239
n max	106	46	n max	1951	1249
average age:	40.2	48.2		41.2	49.0


^(*) in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: Portugal


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0












DATA FOR: **Portugal**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0







Living with lupus in 2020 - Country level data

DATA FOR: 0

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org